Developing androgen receptor targeting for salivary gland cancers

Por Ho, A L
Publicado no Ann Oncol (2018)

A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSC...

Por Dunn, L. A., Fury, M. G., Xiao, H., Baxi, S. S., Sherman, E. J., Korte, S., Pfister, C., Haque, S., Katabi, N., Ho, A. L., Pfister, D. G.
Publicado no Ann Oncol (2017)

A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma

Por Ho, A. L., Dunn, L., Sherman, E. J., Fury, M. G., Baxi, S. S., Chandramohan, R., Dogan, S., Morris, L. G. T., Cullen, G. D., Haque, S., Sima, C. S., Ni, A., Antonescu, C. R., Katabi, N., Pfister, D. G.
Publicado no Ann Oncol (2016)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Por Drilon, A., Li, G., Dogan, S., Gounder, M., Shen, R., Arcila, M., Wang, L., Hyman, D. M., Hechtman, J., Wei, G., Cam, N. R., Christiansen, J., Luo, D., Maneval, E. C., Bauer, T., Patel, M., Liu, S. V., Ou, S. H. I., Farago, A., Shaw, A., Shoemaker, R. F., Lim, J., Hornby, Z., Multani, P., Ladanyi, M., Berger, M., Katabi, N., Ghossein, R., Ho, A. L.
Publicado no Ann Oncol (2016)